Related Experiment Video

Updated: Jun 22, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

EGFR-directed therapies to treat non-small-cell lung cancer

Cheryl Ho1, Janessa Laskin

  • 1British Columbia Cancer Agency, Medical Oncologist, 600 W 10th Avenue, Vancouver, BC V5Z 4E6, Canada. cho@bccancer.bc.ca

Expert Opinion on Investigational Drugs
|July 4, 2009
PubMed

Insights

Targeted therapies, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, show promise for treating non-small cell lung cancer by targeting the EGFR pathway. Further clinical studies are evaluating these novel agents.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Lung cancer is a leading cause of cancer death, with over 200,000 diagnoses and 160,000 deaths in the US in 2008.
  • Non-small cell lung cancer (NSCLC) accounts for over 80% of lung cancers, with chemotherapy offering modest survival benefits.
  • Targeted therapies, particularly those inhibiting the Epidermal Growth Factor Receptor (EGFR) pathway, represent a growing area of research and development.

Purpose of the Study:

  • To review clinical studies of new targeted therapies for lung cancer.
  • To discuss drug development strategies targeting the EGFR pathway.
  • To highlight the role of EGFR inhibitors in managing NSCLC.

Main Methods:

  • Review of clinical studies involving targeted therapies for lung cancer.
  • Analysis of drug development pipelines for EGFR-directed agents.
  • Discussion of the molecular mechanisms of EGFR signaling in cancer.

Main Results:

  • Two main classes of EGFR-targeting drugs have been developed: small molecule tyrosine kinase inhibitors (TKIs) and monoclonal antibodies.
  • These agents target key downstream effects of EGFR activation, including cell proliferation and angiogenesis.
  • Clinical studies are evaluating the efficacy and safety of these novel therapies in lung cancer patients.

Conclusions:

  • Targeted therapies directed at the EGFR pathway offer a promising new avenue for lung cancer treatment.
  • Continued research and clinical trials are essential to optimize the use of these agents in NSCLC.
  • The development of TKIs and monoclonal antibodies represents a significant advancement in personalized lung cancer therapy.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...